- Conditions
- Breast Cancer, Hereditary Breast and Ovarian Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 3,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2026
- U.S. locations
- 11
- States / cities
- Hays, Kansas • Kansas City, Kansas • Overland Park, Kansas + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 10,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Amyloidosis
- Interventions
- Doxycycline 100 mg po bid x 12 months
- Drug
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Lebrikizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more
- Conditions
- Hypopituitarism
- Interventions
- Arimidex (Anastrozole), Placebo, Growth Hormone
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 11 Years to 18 Years · Male only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Cystic Fibrosis
- Interventions
- LUM/IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 17
- States / cities
- Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more
- Conditions
- Scoliosis
- Interventions
- Not listed
- Lead sponsor
- St. Justine's Hospital
- Other
- Eligibility
- 10 Years to 15 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 4
- States / cities
- San Diego, California • Wilmington, Delaware • Miami, Florida + 1 more
- Conditions
- Autistic Disorder, Autism, Early Infantile, Autism, Infantile, Asperger Syndrome
- Interventions
- Not listed
- Lead sponsor
- Yellen & Associates, Inc.
- Other
- Eligibility
- 5 Years to 25 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Northridge, California
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG, poly ICLC, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
- Interventions
- Pathogen Reduced Cryoprecipitated Fibrinogen Complex
- Biological
- Lead sponsor
- Cerus Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Miami, Florida • Baltimore, Maryland + 1 more
- Conditions
- Phenylketonuria, Galactosemia, Inborn Errors of Metabolism
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Severe Combined Immunodeficiency
- Interventions
- Gene transfer
- Biological
- Lead sponsor
- David Williams
- Other
- Eligibility
- Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Boston, Massachusetts • Cincinnati, Ohio
- Conditions
- Vaso-occlusive Crisis, Sickle Cell Disease
- Interventions
- Saline, MST-188
- Drug
- Lead sponsor
- Mast Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Oakland, California + 43 more
- Conditions
- Cystic Fibrosis, Exocrine Pancreatic Insufficiency
- Interventions
- EUR-1008 (APT-1008)
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- Up to 7 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 11 more
- Conditions
- Stomach Neoplasms, Stomach Cancer, Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS), Hereditary Diffuse Gastric Cancer (HDGC), Familial Diffuse Gastric Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 733 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non Malignant Disorders, Immunodeficiencies, Congenital Marrow Failures, Hemoglobinopathies, Inborn Errors of Metabolism, Sickle Cell, Thalassemia, Lysosomal Storage Disease
- Interventions
- Unrelated Umbilical Cord Blood Transplant, Reduced Intensity Conditioning
- Biological · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Li-Fraumeni Syndrome
- Interventions
- Whole Body MRI
- Device
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Gaucher Disease
- Interventions
- no intervention
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Dermatitis, Atopic
- Interventions
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 764 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Henrico, Virginia
- Conditions
- Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ataxia Telangiectasia, Familial Atypical Mole-Malignant Melanoma Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Hereditary Pancreatitis
- Interventions
- Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
- Other
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Atopic Dermatitis
- Interventions
- Hydrogel vehicle, Eucerin Lotion
- Drug
- Lead sponsor
- Derm Research, PLLC
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Non-syndromic Retinitis Pigmentosa
- Interventions
- Gene therapy: GS030-DP AND Medical device: GS030-MD
- Combination Product
- Lead sponsor
- GenSight Biologics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cystic Fibrosis
- Interventions
- Acute Antioxidant, Chronic Antioxidant, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome
- Interventions
- Medically-supervised withdrawal, Opioid agonist treatment, Comprehensive clinical care
- Other · Behavioral
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years to 41 Years · Female only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- Asheville, North Carolina • Chapel Hill, North Carolina • Burlington, Vermont + 1 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Exercising, Optical and Magnetic Resonance Imaging and Spectroscopy
- Other · Procedure
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 10 Years to 55 Years · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida